DannyHiroshiSugimotoMDCPI

PubMed

• Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 di...
  Elena A Christofides, Orlando Puente, Paul Norwood, Douglas Denham, Hiralal Maheshwari, Michael Lillestol, Terence Hart, Samer Nakhle, Anurekha Chadha, David Fitz-Patr...> ;Diabetes, Obesity & Metabolism. 2024 Apr 1
• Cardiometabolic risk factors efficacy of semaglutide in the STEP program.
  Anastassia Amaro, Neil S Skolnik, Danny Sugimoto> ;Postgraduate Medicine. 2022 Jan 1
• 10 citations
  Efficacy and safety of semaglutide for weight management: evidence from the STEP program.
  Anastassia Amaro, Danny Sugimoto, Sean Wharton> ;Postgraduate Medicine. 2022 Jan 1
• 5 citations
  Effects of Dietary Self-Monitoring, Physical Activity, Liraglutide 3.0 mg, and Placebo on Weight Loss in the SCALE IBT Trial.
  Jena Shaw Tronieri, Anthony N. Fabricatore, Thomas A. Wadden, Pernille Auerbach, Lars Endahl, Danny Sugimoto, Domenica Rubino> ;Obesity Facts. 2020 Nov 16
• 67 citations
  Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Contro...
  W. Timothy Garvey, Andreas L. Birkenfeld, Dror Dicker, Geltrude Mingrone, Sue D. Pedersen, Altynai Satylganova, Dorthe Skovgaard, Danny Sugimoto, Camilla B. Jensen, Of...> ;Diabetes Care. 2020 Mar 3
• 67 citations
  Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial
  Thomas A. Wadden, Jena Shaw Tronieri, Danny Sugimoto, Michael T. Lund, Pernille Auerbach, Camilla B. Jensen, Domenica Rubino> ;Obesity. 2020 Mar 1
• 3 citations
  IDegLira improves patient-reported outcomes while using a simple regimen with fewer injections and dose adjustments compared with basal-bolus therapy.
  Eden Miller, Ankur Doshi, Randi Grøn, Esteban Jódar, Petra Őrsy, Mattis F. Ranthe, Danny H. Sugimoto, Nikolaos Tentolouris, Adie Viljoen, Liana K. Billings> ;Diabetes, Obesity & Metabolism. 2019 Dec 1
• 2 citations
  Efficacy of iGlarLixi, a fixed-ratio combination of insulin glargine and lixisenatide, in patients with type 2 diabetes stratified as at high or low risk according to ...
  Danny H. Sugimoto, Terry Dex, William Stager, Vanita R. Aroda> ;Diabetes, Obesity & Metabolism. 2018 Nov 1
• 179 citations
  Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial.
  Helena W. Rodbard, Ildiko Lingvay, John C. Reed, Raymond de la Rosa, Ludger Rose, Danny Sugimoto, Eiichi Araki, Pei Ling Chu, Nelun Wijayasinghe, Paul Norwood> ;The Journal of Clinical Endocrinology and Metabolism. 2018 Jun 1
• 11 citations
  Combination therapy with insulin glargine plus metformin but not insulin glargine plus sulfonylurea provides similar glycemic control to triple oral combination therap...
  Priscilla Hollander, Danny Sugimoto, Aleksandra Vlajnic, Charles Kilo> ;Journal of Diabetes and Its Complications. 2015 Nov 1
• 1 citations
  The TRINITY Study: distribution of systolic blood pressure reductions.
  Danny H Sugimoto, Steven G. Chrysant, Michael Melino, James Lee, Victor Fernandez, Reinilde Heyrman> ;Integrated Blood Pressure Control. 2013 Jul 12
• 180 citations
  Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.
  Julio Rosenstock, Danny Sugimoto, Poul Strange, John A. Stewart, Erika Soltes-Rak, George Dailey> ;Diabetes Care. 2006 Mar 1
• Join now to see all

Journal Articles

• Efficacy of iGlarLixi, a Fixed‐Ratio Combination of Insulin Glargine and Lixisenatide, in Patients with Type 2 Diabetes Stratified as High and Low Risk According to HE...  
  Danny Sugimoto, MD, Diabetes, Obesity and Metabolism